HER2 Blockade: Is Combination Therapy Better Than Monotherapy?

ISSN： 1527-2729

Source： Current Treatment Options in Oncology, Vol.11, Iss.3-4, 2010-12, pp. : 63-65

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/ neu in Patients with Breast Cancer

By Taucher Susanne

Breast Cancer Research and Treatment, Vol. 82, Iss. 3, 2003-01 ,pp. : 207-213

Springer Publishing Company

Access to resources Recommend Favorite

Are there racial/ethnic disparities among women younger than 40 undergoing mammography?

By Kapp Julie

Breast Cancer Research and Treatment, Vol. 124, Iss. 1, 2010-11 ,pp. : 213-222

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of Combination Therapy Versus Monotherapy

By Krainer Michael

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 11-15

Springer Publishing Company

Access to resources Recommend Favorite

Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?

By Lin Nancy

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 129-131

Springer Publishing Company

Access to resources Recommend Favorite

Local treatment of mixed osteolytic/osteoblastic spinal metastases: is photodynamic therapy effective?

By Wise-Milestone L.

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 899-908

Springer Publishing Company

Access to resources Recommend Favorite